Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Allergan Licenses Dry Eye Treatment
by Michael McCoy
November 9, 2015
| A version of this story appeared in
Volume 93, Issue 44
Allergan has licensed rights to tavilermide, a peptidomimetic compound for the treatment of dry eye disease, from the Canadian firm Mimetogen Pharmaceuticals. Allergan will pay $50 million and fund Phase III development of the compound, which Mimetogen licensed from McGill University and the Lady Davis Institute for Medical Research in Montreal. Unlike other dry eye compounds, tavilermide induces the production of mucin, a naturally occurring component of the tear film, Allergan says. Pfizer is in talks to acquire Allergan for more than $120 billion.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter